BACKGROUND: The optimal means of achieving therapeutic oral anticoagulation in the outpatient setting has not been determined. OBJECTIVE: To compare a 10-mg dosing nomogram with a 5-mg nomogram that has been suggested to be sufficient for @entity1229 initiation. DESIGN: Randomized, controlled clinical trial. SETTING: Outpatient @entity1211 services of four tertiary care hospitals. @entity1 : 201 of 210 consecutive @entity1 with objectively confirmed diagnoses of @entity1211 . INTERVENTION: All @entity1 were treated with subcutaneous low-molecular-weight heparin for a minimum of 5 days until a therapeutic international normalized ratio (INR) was achieved. @entity1 were randomly assigned to initially receive a 10-mg or 5-mg dose of @entity1229 . MEASUREMENTS: The primary end point was time in days to therapeutic INR. Secondary end points were the proportion of @entity1 who had achieved a therapeutic INR by day 5, the total number of INR assessments, the number of INR measurements greater than 5.0, incidence of recurrent @entity1211 and @entity548 , and survival. RESULTS: 210 consecutive @entity1 met the inclusion criteria. Of these, 9 were excluded and 201 were randomly assigned to study groups (104 to the 10-mg group and 97 to the 5-mg group). Demographic characteristics of both groups were similar. @entity1 in the 10-mg group achieved therapeutic INR 1.4 days earlier than @entity1 in the 5-mg group (P < 0.001). Eighty-three percent of @entity1 in the 10-mg group achieved a therapeutic INR by day 5 versus 46% in the 5-mg group (P < 0.001). Fewer INR assessments were performed in the 10-mg group than in the 5-mg group (8.1 vs. 9.1; P = 0.04). There were no significant differences between the two groups in recurrent events, @entity548 , survival, and number of INR measurements greater than 5.0. CONCLUSION: The 10-mg @entity1229 initiation nomogram is superior to the 5-mg nomogram because it allows more rapid achievement of a therapeutic INR.

Comparison of 10-mg and 5-mg @entity1229 initiation nomograms together with low-molecular-weight heparin for outpatient treatment of XXXX . A randomized, double-blind, controlled trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['acute venous thromboembolism', 'venous thromboembolism'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin'] @entity548 :: ('MESH:D006470', 'Disease') :: ['major bleeding']
@entity1211 :: (MESH:D054556,Disease) :: ['acute venous thromboembolism']
